Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
about
Drug Use on Mont Blanc: A Study Using Automated Urine CollectionThe ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.Prevalence of legal and illegal stimulating agents in sports.Are prescription stimulants "smart pills"? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals.Adrenergic metabolic and hemodynamic effects of octopamine in the liver.Drug metabolism in the horse: a review.Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.Prevalence of illicit drug use among the Italian athlete population with special attention on drugs of abuse: a 10-year review.Doping in sport and exercise: anabolic, ergogenic, health and clinical issues.Drugs in sport.Uncommon drug abuse: An anesthetist dilemma.Acute consumption of p-synephrine does not enhance performance in sprint athletes.The athlete biological passport: ticket to a fair Commonwealth Games.Photobleaching-based method to individualize irradiation time during interstitial 5-aminolevulinic acid photodynamic therapy.Preparticipation Evaluation of the Young Athlete: What an Orthopaedic Surgeon Needs to Know.The action of p-synephrine on hepatic carbohydrate metabolism and respiration occurs via both Ca2+-mobilization and cAMP production
P2860
Q28552629-8EAD0546-8D08-4285-A106-FB5E4262FD9CQ34025177-D8A47FEF-D58C-4943-BCAD-A2E357BA0DBAQ34177175-B79A1111-2654-46F9-B67A-3EA890B85DAEQ36666847-97CC0422-F189-4021-A40E-B8B96EE05B33Q37375395-4CDD9229-5FCC-46C1-B867-21F9B9E09F64Q37802313-F338DFEC-EA06-47CC-8FCA-9EEC016325F0Q37805634-E1D6BDF2-10F6-484F-A9BB-BFBFD79EEC0BQ37833561-BFD65A15-C95F-4AD5-B967-D7DF20C4BC36Q38589015-016625E0-B617-4994-9CC6-655C92088BFBQ43103569-3ABCA91E-1CD3-4C37-8445-3149BEFEC41CQ43213698-C5B34479-CE80-48F0-BA68-B02C31DBD170Q47908750-37DCCC88-A6E1-4EB8-953E-DEB83A69A0CCQ48066335-83B12656-A415-4BCE-A41D-0E88C15659A9Q48934431-3F574C26-503D-4F76-8BFE-A353742A90A9Q52545090-AF659FFE-BA5F-492F-975F-2CB5259BA16FQ57570291-B14F8A1C-FCB1-4390-82A4-3474BE0692C7
P2860
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@ast
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@en
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@en-gb
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@nl
type
label
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@ast
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@en
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@en-gb
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@nl
prefLabel
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@ast
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@en
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@en-gb
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@nl
P2860
P3181
P356
P1476
Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)
@en
P2093
J R Docherty
P2860
P304
P3181
P356
10.1038/BJP.2008.124
P407
P577
2008-06-01T00:00:00Z